At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Axitinib +1 moredrug
Likely dose
Axitinib 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
In Brief
A Phase 2 clinical trial evaluating Axitinib and Observation for Recurrent ACC, metastaticACC, Unreaectable ACC. Completed, enrolled 60 participants across 1 site.
Detailed Summary
To understand efficacy of axitinib in recurred or metastatic adenoid cystic carcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionDec 2017
Study CompletionAug 2020
TodayJul 2026
First PostedAug 8, 2016
Enrollment StartSep 1, 2016
Primary CompletionDec 1, 2017
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.9 years ago
Interventions
Axitinibdrug
Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
Observationother
this group is observational ones.